Comments

Rhythm Pharmaceuticals Stock Price, Quotes and Forecasts

Q: What sector and industry does Rhythm Pharmaceuticals (RYTM) operate in?

Rhythm Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

RYTMNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$52.04

-2.19-4.04%

At close: -

$52.04

0.000.00%

After Hours: 4:00 PM EDT

Rhythm Pharmaceuticals (RYTM) Forecast

News Earnings Rhythm Pharmaceuticals (RYTM) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Rhythm Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:RYTM | Benzinga

Explore Rhythm Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for RYTM.

Open	$54.23
Close	$52.04
Volume / Avg.	902.54K / 520.84K
Day Range	$51.87 - $54.45
52 Wk Range	35.17 - 68.58
Market Cap	$3.29B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	46
Short Interest	12.13%
Days to Cover	9.05

Recent News

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Rhythm Pharmaceuticals targets rare obesity disorders with its drug Imcivree, showing strong growth in sales and potential for significant market expansion

Vandana Singh

Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKesson

The "Mad Money" host recommended buying some Marvell Technology, and then wait until under $60 to buy the rest.

Avi Kapoor

Rare Genetic Diseases Of Obesity-Focused Rhythm Pharma's Bardet-Biedl Syndrome Drug Meets Primary Goal In Pediatric Trial

During the R&D event for investors, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) released new topline data from its Phase 3 pediatrics trial evaluating one year of setmelanotide in patients aged two and below six years with Bardet-Biedl syndrome (BBS) or proopiomelanocortin (POMC) or leptin recep

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Oct 24

Nov 24

Dec 24

Feb

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$54.23
Close	$52.04
Volume / Avg.	902.54K / 520.84K
Day Range	$51.87 - $54.45
52 Wk Range	35.17 - 68.58
Market Cap	$3.29B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	46
Short Interest	12.13%
Days to Cover	9.05

About Rhythm Pharmaceuticals Inc.

Sector

Health Care

Industry

Biotechnology

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the dev...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Rhythm Pharmaceuticals (RYTM) stock?

You can purchase shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) through any online brokerage.

View our list of the best stock brokerages

Who are Rhythm Pharmaceuticals (RYTM) competitors?

Other companies in Rhythm Pharmaceuticals’s space includes: Immunovant (NASDAQ:IMVT), Avidity Biosciences (NASDAQ:RNA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Ionis Pharmaceuticals (NASDAQ:IONS) and SpringWorks Therapeutics (NASDAQ:SWTX).

What is the forecast, or price target, for Rhythm Pharmaceuticals (RYTM) stock?

Rhythm Pharmaceuticals has a consensus price target of $61.20.

What is the current price for Rhythm Pharmaceuticals (RYTM)?

The stock price for Rhythm Pharmaceuticals (NASDAQ: RYTM) is $52.04 last updated March 21, 2025 at 4:00 PM EDT.

Does Rhythm Pharmaceuticals (RYTM) pay a dividend?

There are no upcoming dividends for Rhythm Pharmaceuticals.

When is Rhythm Pharmaceuticals (NASDAQ:RYTM) reporting earnings?

Rhythm Pharmaceuticals’s Q1 earnings are confirmed for Tuesday, May 6, 2025.

Is Rhythm Pharmaceuticals (RYTM) going to split?

There is no upcoming split for Rhythm Pharmaceuticals.

What sector and industry does Rhythm Pharmaceuticals (RYTM) operate in?

Rhythm Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.